Plasma Lipoproteins and Progression of Coronary Artery Disease Evaluated by Angiography and Clinical Events

BackgroundThere is considerable evidence that remnants of triglyceride-rich lipoproteins may be particularly atherogenic. Methods and ResultsLevels of lipoprotein lipids and of apolipoprotein B in low-density lipoproteins were measured in 335 men and women enrolled in a study in which quantitative coronary angiography was carried out at 2-year intervals. Clinical events related to coronary disease occurred in 129 patients during the trial and in the subsequent follow-up period of 4 to 6 years. In multivariate analysis controlled for a number of nonlipid risk factors, high-density lipoprotein cholesterol was inversely related to the mean percentage increase in coronary artery stenosis in both men and women. Neither plasma triglycerides nor low-density lipoprotein cholesterol, triglycerides, or apolipoprotein B was related to change in stenosis, but a measure of remnants of triglyceride-rich lipoproteins, which included cholesterol in intermediatedensity lipoproteins, was directly related to lesion progression. The same relations for these measures of plasma lipoprotein concentrations were found to hold for clinical events related to coronary artery atherosclerosis. ConclusionsIn patients with established coronary heart disease, increased levels of remnants of triglyceride-rich lipoproteins and decreased levels of high-density lipoproteins appear to promote progression of coronary artery atherosclerosis, which in turn may lead to an untoward clinical event. No such relation could be shown for the level of components of low-density lipoproteins. These and other observations call for reevaluation of relations between particular species of lipoproteins containing apolipoprotein B and the pathogenesis of coronary artery atherosclerosis and coronary heart disease.

[1]  Elisa T. Lee,et al.  Statistical Methods for Survival Data Analysis , 1994, IEEE Transactions on Reliability.

[2]  T. Craven,et al.  Prognostic Significance of Progression of Coronary Atherosclerosis , 1993, Circulation.

[3]  R. Havel,et al.  Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[4]  E. Ziegel.  Statistical Methods for Survival Data Analysis , 1993 .

[5]  M. Emi,et al.  Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2. Evidence for a gene-gene interaction. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[6]  M. Sentí,et al.  Influence of intermediate-density lipoproteins on the accuracy of the Friedewald formula. , 1991, Clinical chemistry.

[7]  D. Waters,et al.  Regression of coronary atherosclerosis: an achievable goal? Review of results from recent clinical trials. , 1991, The American journal of medicine.

[8]  P Théroux,et al.  A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. , 1990, Circulation.

[9]  H. Tyroler,et al.  Overview of clinical trials of cholesterol lowering in relationship to epidemiologic studies. , 1989, The American journal of medicine.

[10]  M. Austin.  Plasma triglyceride as a risk factor for coronary heart disease. The epidemiologic evidence and beyond. , 1989, American journal of epidemiology.

[11]  W C Willett,et al.  Low-density lipoprotein subclass patterns and risk of myocardial infarction. , 1988, JAMA.

[12]  D. Waters,et al.  Design features of a controlled clinical trial to assess the effect of a calcium entry blocker upon the progression of coronary artery disease. , 1987, Controlled clinical trials.

[13]  R. Krauss,et al.  INTERMEDIATE-DENSITY LIPOPROTEINS AND PROGRESSION OF CORONARY ARTERY DISEASE IN HYPERCHOLESTEROLAEMIC MEN , 1987, The Lancet.

[14]  G. Assmann,et al.  Association of apolipoprotein E polymorphism, low-density lipoprotein cholesterol, and coronary artery disease. , 1986, Clinical chemistry.

[15]  P. Nestel,et al.  Lipoprotein predictors of the severity of coronary artery disease in men and women. , 1985, Circulation.

[16]  J. J. Gerbrands,et al.  Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms. , 1985, Circulation.

[17]  Y. Matsuzawa,et al.  Increased frequency of lipoprotein disorders similar to type III hyperlipoproteinemia in survivors of myocardial infarction in Japan. , 1984, Atherosclerosis.

[18]  H. Wieland,et al.  Determination of apolipoprotein B by kinetic (rate) nephelometry. , 1982, Journal of lipid research.

[19]  J. Albers,et al.  Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. , 1982, Clinical chemistry.

[20]  H. Eder,et al.  The clinical significance of the plasma high density lipoproteins. , 1982, The Medical clinics of North America.

[21]  R. Havel.  Familial dysbetalipoproteinemia. New aspects of pathogenesis and diagnosis. , 1982, The Medical clinics of North America.

[22]  H. Mabuchi,et al.  Intermediate‐density Lipoprotein and Cholesterol‐rich Very Low Density Lipoprotein in Angiographically Determined Coronary Artery Disease , 1981, Circulation.

[23]  T. Killip,et al.  The National Heart, Lung, and Blood Institute Coronary Artery Surgery Study (CASS) , 1981 .

[24]  R. Havel,et al.  Radioimmunoassay of human arginine-rich apolipoprotein, apoprotein E. Concentration in blood plasma and lipoproteins as affected by apoprotein E-3 deficiency. , 1980, The Journal of clinical investigation.

[25]  G. Cazzolato,et al.  Relationship between apolipoproteins and chemical components of lipoproteins in survivors of myocardial infarction. , 1980, Atherosclerosis.

[26]  R. Havel,et al.  Characterization of human very low density lipoproteins containing two electrophoretic populations: double pre-beta lipoproteinemia and primary dysbetalipoproteinemia. , 1977, Journal of lipid research.

[27]  O. Faergeman,et al.  Characterization of remnants produced during the metabolism of triglyceride-rich lipoproteins of blood plasma and intestinal lymph in the rat. , 1975, The Journal of clinical investigation.

[28]  R. Havel,et al.  Characterization of subfractions of triglyceride-rich lipoproteins separated by gel chromatography from blood plasma of normolipemic and hyperlipemic humans. , 1972, Journal of lipid research.

[29]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[30]  R. Havel,et al.  Serum lipid and lipoprotein alterations in nephrosis. , 1960, The Journal of clinical investigation.

[31]  J. A. Shannon,et al.  Evaluation of Serum Lipoprotein and Cholesterol Measurements as Predictors of Clinical Complications of Atherosclerosis: Report of a Cooperative Study of Lipoproteins and Atherosclerosis , 1956, Circulation.

[32]  R. Havel,et al.  The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. , 1955, The Journal of clinical investigation.

[33]  J. Gofman,et al.  Lipoproteins, coronary heart disease, and atherosclerosis. , 1954, Physiological reviews.

[34]  R. Havel.  Biology of cholesterol, lipoproteins and atherosclerosis. , 1989, Clinical and experimental hypertension. Part A, Theory and practice.

[35]  S. Shumak,et al.  The association of increased levels of intermediate-density lipoproteins with smoking and with coronary artery disease. , 1987, Circulation.

[36]  R. Krauss,et al.  Identification of multiple subclasses of plasma low density lipoproteins in normal humans. , 1982, Journal of lipid research.